Table 2 Meta-analysis of exercise-based PR for asthma
Outcomes | No. of RCTs | No. of participants | Effect estimate (95% CI) | I2 (%) | P value | |
|---|---|---|---|---|---|---|
Primary outcome measures | ||||||
Quality of life | ||||||
| Â | AQLQ (Overall QOL) | 4 | 198 | MD 0.39 (0.02, 0.76) | 0 | 0.04 |
| Â | AQLQ (Activity domain) | 4 | 196 | MD 0.58 (0.21, 0.94) | 0 | 0.002 |
| Â | AQLQ (Symptom domain) | 4 | 196 | MD 0.52 (0.19, 0.85) | 0 | 0.002 |
|  | AQLQ (Emotion domain) | 4 | 196 | MD 0.53 (− 0.03, 1.09) | 0 | 0.06 |
| Â | AQLQ (Environment domain) | 4 | 196 | MD 0.56 (0.00, 1.11) | 0 | 0.05 |
Secondary outcome measures | ||||||
Asthma control | ACQ | 5 | 215 | SMD − 0.25 (0.51, 0.02) | 0 | 0.07 |
Asthma symptom-free days | 2 | 94 | MD 3.35 (− 0.21, 6.90) | 17 | 0.07 | |
Pulmonary function | FEV1 | 5 | 242 | MD 0.10 (− 0.08, 0.29) | 74 | 0.28 |
FVC | 3 | 163 | MD 0.23 (0.08, 0.38) | 0 | 0.003 | |
PEF | 2 | 112 | MD 0.39 (0.21, 0.57) | 0 | < 0.0001 | |
Exercise tolerance | 6 MWD | 3 | 94 | MD 34.09 (2.51, 65.66) | 0 | 0.03 |
VO2 max | 3 | 141 | MD 4.45 (3.32, 5.58) | 0 | < 0.00001 | |